Working… Menu
Trial record 1 of 44 for:    CA-9
Previous Study | Return to List | Next Study

Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer (CA9CRM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00942058
Recruitment Status : Terminated (Difficult for recruiting)
First Posted : July 20, 2009
Last Update Posted : January 29, 2014
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Saint Etienne